Skip to search boxSkip to navigationSkip to main content

Prehospital synergy: Tranexamic acid and blood transfusion in patients at risk for hemorrhage

  • Andrew Paul Deeb
    ,
  • Lara Hoteit
    ,
  • Shimena Li
    ,
  • Francis X. Guyette
    ,
  • Brian J. Eastridge
    ,
  • Raminder Nirula
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

<p>BACKGROUND Growing evidence supports improved survival with prehospital blood products. Recent trials show a benefit of prehospital tranexamic acid (TXA) administration in select subgroups. Our objective was to determine if receiving prehospital packed red blood cells (pRBC) in addition to TXA improved survival in injured patients at risk of hemorrhage. METHODS We performed a secondary analysis of all scene patients from the Study of Tranexamic Acid during Air and ground Medical Prehospital transport trial. Patients were randomized to prehospital TXA or placebo. Some participating EMS services utilized pRBC. Four resuscitation groups resulted: TXA, pRBC, pRBC+TXA, and neither. Our primary outcome was 30-day mortality and secondary outcome was 24-hour mortality. Cox regression tested the association between resuscitation group and mortality while adjusting for confounders. RESULTS A total of 763 patients were included. Patients receiving prehospital blood had higher Injury Severity Scores in the pRBC (22 [10, 34]) and pRBC+TXA (22 [17, 36]) groups than the TXA (12 [5, 21]) and neither (10 [4, 20]) groups (p < 0.01). Mortality at 30 days was greatest in the pRBC+TXA and pRBC groups at 18.2% and 28.6% compared with the TXA only and neither groups at 6.6% and 7.4%, respectively. Resuscitation with pRBC+TXA was associated with a 35% reduction in relative hazards of 30-day mortality compared with neither (hazard ratio, 0.65; 95% confidence interval, 0.45-0.94; p = 0.02). No survival benefit was observed in 24-hour mortality for pRBC+TXA, but pRBC alone was associated with a 61% reduction in relative hazards of 24-hour mortality compared with neither (hazard ratio, 0.39; 95% confidence interval, 0.17-0.88; p = 0.02). CONCLUSION For injured patients at risk of hemorrhage, prehospital pRBC+TXA is associated with reduced 30-day mortality. Use of pRBC transfusion alone was associated with a reduction in early mortality. Potential synergy appeared only in longer-term mortality and further work to investigate mechanisms of this therapeutic benefit is needed to optimize the prehospital resuscitation of trauma patients. LEVEL OF EVIDENCE Therapeutic/Care Management; Level III.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 52-58 (7 pages)

Journal (Volume, Issue Number)

Journal of Trauma and Acute Care Surgery (Volume 93, Issue 1)

Publication milestones

  • Published - 07/01/2022

Publication status

Published - 07/01/2022

ISSN

2163-0755

Publication IDs

  • Scopus: 85132455588
  • PubMed: 35393385

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.08
Fractional count
11
Fractional count
0.92
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
53
Citation count
20

Funding Details

The original trial was funded by grant W81XWH 13-2-0080 from the US Army Medical Research and Material Command. No funding or support was directly received to perform the current study. DISCLOSURE
FundersFunding number
NHLBI
T32HL098036
MRMC
-